NCT05007106
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior therapy of an anti-programmed cell-death (PD-1), anti-PD-L1/2 (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab), or anti-TIGIT agent
https://ClinicalTrials.gov/show/NCT05007106